Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease-Reply

Charbel Moussa^{1

2

3

4}

Affiliations

¹ Department of Neurology, Georgetown University Medical Center, Washington, DC.
² Laboratory for Dementia and Parkinsonism, Georgetown University Medical Center, Washington, DC.
³ Translational Neurotherapeutics Program, Parkinson's Foundation Center of Excellence, Georgetown University Medical Center, Washington, DC.
⁴ Lewy Body Dementia Research Center of Excellence, Department of Neurology, Georgetown University Medical Center, Washington, DC.

Comment

Charbel Moussa. JAMA Neurol. 2020.

. 2020 Aug 1;77(8):1039-1040.

doi: 10.1001/jamaneurol.2020.1931.

Charbel Moussa^{1

2

3

4}

¹ Department of Neurology, Georgetown University Medical Center, Washington, DC.
² Laboratory for Dementia and Parkinsonism, Georgetown University Medical Center, Washington, DC.
³ Translational Neurotherapeutics Program, Parkinson's Foundation Center of Excellence, Georgetown University Medical Center, Washington, DC.
⁴ Lewy Body Dementia Research Center of Excellence, Department of Neurology, Georgetown University Medical Center, Washington, DC.

No abstract available

Comment on

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.
Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, Yusuf N, Starr NJ, Anjum M, Arellano J, Howard HH, Shi W, Mulki S, Kurd-Misto T, Matar S, Liu X, Ahn J, Moussa C. Pagan FL, et al. JAMA Neurol. 2020 Mar 1;77(3):309-317. doi: 10.1001/jamaneurol.2019.4200. JAMA Neurol. 2020. PMID: 31841599 Free PMC article. Clinical Trial.
Dopamine Metabolite Biomarkers and Testing for Disease Modification in Parkinson Disease.
LeWitt PA. LeWitt PA. JAMA Neurol. 2020 Aug 1;77(8):1038-1039. doi: 10.1001/jamaneurol.2020.1928. JAMA Neurol. 2020. PMID: 32597929 No abstract available.